Dithiocarbamates and viral IL-10 collaborate in the immortalization and evasion of immune response in EBV-infected human B lymphocytes

Chemico-Biological Interactions

Volumn 172, Issue 1, 2008, Pages 81-92

  Irons, Richard D ^a,b,c,d,e   Le, Anh Tuan ^b  

^a Institutes of Brain Science   (China)

^b School of Pharmacy   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Cinpathogen Inc   (United States)

^e Cinpathogen Inc   (China)

Author keywords

B lymphocytes; Dithiocarbamates; Epstein Barr virus; IL 10; Immune evasion

Indexed keywords

DITHIOCARBAMIC ACID; INTERLEUKIN 10; ORGANOSULFUR DERIVATIVE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL IMMORTALIZATION; CELL SURVIVAL; CELL TRANSFORMATION; EPSTEIN BARR VIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE TRANSFORMATION; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR EPIDEMIOLOGY; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS GENE; VIRUS MUTANT; VIRUS RECOMBINANT;

B-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; INTERLEUKIN-10; T-LYMPHOCYTES; THIOCARBAMATES; TIME FACTORS;

HUMAN HERPESVIRUS 4;

EID: 39649090753     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2007.11.005     Document Type: Article

References (68)

1. Pallesen G., Hamilton-Dutoit S.J., and Zhou X. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. Adv. Cancer Res. 62 (1993) 179-239
2. Thomas J.A., Hotchin N.A., Allday M.J., Amlot P., Rose M., Yacoub M., and Crawford D.H. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49 (1990) 944-953
3. Thomas J.A., Allday M.J., and Crawford D.H. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res. 57 (1991) 329-380
4. Caldwell R.G., Wilson J.B., Anderson S.J., and Longnecker R. Epstein-Barr virus Lmp2a drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9 (1998) 405-411
5. Gires O., Zimber-Strobl U., Gonnella R., Ueffing M., Marschall G., Zeidler R., Pich D., and Hammerschmidt W. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16 (1997) 6131-6140
6. Henderson S., Huen D., Rowe M., Dawson C., Johnson G., and Rickinson A. Epstein-Barr virus-coded Bhrf1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. PNAS 90 (1993) 8479-8483
7. Finke J., Fritzen R., Ternes P., Trivedi P., Bross K.J., Lange W., Mertelsmann R., and Dolken G. Expression of Bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood 80 (1992) 459-469
8. Gangappa S., van Dyk L.F., Jewett T.J., Speck S.H., and Virgin H.W. Identification of the in vivo role of a viral Bcl-2. J. Exp. Med. 195 (2002) 931-940
9. IARC, Other data relevant to an evaluation of carcinogenicity and its mechanisms, 70 (1997).
10. Kieff E., and Rickinson A.B. Epstein-Barr virus and its replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology (1996), Lippincott-Raven, Philadelphia 2343-2396
11. Jin X.W., and Speck S.H. Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral Bamhi C promoter. J. Virol. 66 (1992) 2846-2852
12. Zimber-Strobl U., Suentzenich K.O., Laux G., Eick D., Cordier M., Calender A., Billaud M., Lenoir G.M., and Bornkamm G.W. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J. Virol. 65 (1991) 415-423
13. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., Rickinson A., and Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64 (1990) 2309-2318
14. Tierney R.J., Steven N., Young L.S., and Rickinson A.B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68 (1994) 7374-7385
15. Mahot S., Sergeant A., Drouet E., and Gruffat H. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. J. Gen. Virol. 84 (2003) 965-974
16. Moore K.W., Vieira P., Fiorentino D.F., Trounstine M.L., Khan T.A., and Mosmann T.R. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248 (1990) 1230-1234
17. Vieira P., de Waal-Malefyt R., Dang M.N., Johnson K.E., Kastelein R., Fiorentino D.F., deVries J.E., Roncarolo M.G., Mosmann T.R., and Moore K.W. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. PNAS 88 (1991) 1172-1176
18. Miyazaki I., Cheung R.K., and Dosch H.M. Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. J. Exp. Med. 178 (1993) 439-447
19. Touitou R., Cochet C., and Joab I. Transcriptional analysis of the Epstein-Barr virus interleukin-10 homologue during the lytic cycle. J. Gen. Virol. 77 (1996) 1163-1168
20. Stewart J.P., Behm F.G., Arrand J.R., and Rooney C.M. Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 200 (1994) 724-732
21. Bejarano M.T., and Masucci M.G. Interleukin-10 abrogates the inhibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood 92 (1998) 4256-4262
22. Stuart A.D., Stewart J.P., Arrand F.R., and Mackett M. The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. Oncogene 11 (1995) 1711-1719
23. Levy Y., and Brouet J.-C. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J. Clin. Invest. 93 (1994) 424-428
24. Ohshima K., Suzumiya J., Akamatu M., Takeshita M., and Kikuchi M. Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4+ and CD8+ T lymphocytes. Int. J. Cancer 62 (1995) 5-10
25. Salek-Ardakani S., Arrand J.R., and Mackett M. Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV. Virology 304 (2002) 342-351
26. Liu Y., de Waal Malefyt R., Briere F., Parham C., Bridon J.M., Banchereau J., Moore K.W., and Xu J. The EBV Il-10 homologue is a selective agonist with impaired binding to the Il-10 receptor. J. Immunol. 158 (1997) 604-613
27. Yoon S.I., Jones B.C., Logsdon N.J., Walter M.R., and Same Structure. Different function crystal structure of the Epstein-Barr virus Il-10 bound to the soluble Il-10r1 chain. Structure 13 (2005) 551-564
28. Swaminathan S., Hesselton R., Sullivan J., and Kieff E. Epstein-Barr virus recombinants with specifically mutated BCRF1 genes. J. Virol. 67 (1993) 7406-7413
29. Environmental Protection Agency, EPA compendium of registered pesticides (1974) Volume 1 of EPA compendium of registered pesticides which is issued in 5 volumes each updated by continuing supplements and cumulated irregularly. Item 473-B-3.
30. Nanni O., Amadori D., Lugaresi C., Falcini F., Scarpi E., Saragoni A., and Buiatti E. Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on a priori exposure matrices. Occup. Environ. Med. 53 (1996) 652-657
31. Alexander D.D., Mink P.J., Adami H.O., Chang E.T., Cole P., Mandel J.S., and Trichopoulos D. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int. J. Cancer 120 (2007) 1-39
32. Wilcosky T.C., Checkoway H., Marshall E.G., and Tyroler H.A. Cancer mortality and solvent exposures in the rubber industry. Am. Ind. Hyg. Assoc. J. 45 12 (1984) 809-811
33. Irons R.D., and Pyatt D.W. Dithiocarbamates as potential confounders in butadiene epidemiology. Carcinogenesis 19 (1998) 539-542
34. Aragonés J., López-Rodríquez C., Corbí A., Del Arco P.G., López-Cabrera M., De Landázuri M.O., and Redondo J.M. Dithiocarbamates trigger differentiation and induction of CD11c gene through AP-1 in the myeloid lineage. J. Biol. Chem. 271 (1996) 10924-10931
35. Burkitt M.J., Bishop H.S., Milne L., Tsang S.Y., Provan G.J., Nobel C.S.I., Orrenius S., and Slater A.F.G. Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species. Arch. Biochem. Biophys. 353 (1998) 73-84
36. Shenep J.L., Hughes W.T., Flynn P.M., Roberson P.K., Behm F.G., Fullen G.H., Kovnar S.G., Guito K.P., and Brodkey T.O. Decreased counts of blood neutrophils, monocytes, and platelets in human immunodeficiency virus-infected children and young adults treated with diethyldithiocarbamate. Antimicrob. Agents Chemother. 38 (1994) 1644-1646
37. + T lymphocytes. Toxicology 128 (1998) 83-90
38. Yu I.J., Park J.D., Park E.S., Song K.S., Han K.T., Han J.H., Chung Y.H., Choi B.S., Chung K.H., and Cho M.H. Manganese distribution in brains of Sprague-Dawley rats after 60 days of stainless steel welding-fume exposure. Neurotoxicology 24 (2003) 777-785
39. Cereser C., Boget S., Parvaz P., and Revol A. Thiram-induced cytotoxicity is accompanied by a rapid and drastic oxidation of reduced glutathione with consecutive lipid peroxidation and cell death. Toxicology 163 (2001) 153-162
40. Zenzen V., Fauth E., Zankl H., Janzowski C., and Eisenbrand G. Mutagenic and cytotoxic effectiveness of zinc dimethyl and zinc diisononyldithiocarbamate in human lymphocyte cultures. Mutat. Res. 497 (2001) 89-99
41. Ruhlmann A., and Nordheim A. Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. Immunobiology 198 (1997) 192-206
42. Henle W., Diehl V., Kohn G., Hausen H., and Henle G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157 (1967) 1064-1065
43. Pope J.H., Horne M.K., and Scott W. Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int. J. Cancer 3 (1968) 857-866
44. Purtilo D.T., Strobach R.S., Okano M., and Davis J.R. Epstein-Barr virus-associated lymphoproliferative disorders. Lab. Invest. 67 (1992) 5-23
45. Groux H., Bigler M., de Vries J.E., and Roncarolo M.G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med. 184 (1996) 19-29
46. Muller A., Schmitt L., Raftery M., and Schonrich G. Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction. Eur. J. Immunol. 28 (1998) 3488-3498
47. Irons R.D., Stillman W.S., Pyatt D.W., Yang Y., Le A., Gustafson D.L., and Zheng J.H. Comparative toxicity of dithiocarbamates and butadiene metabolites in human lymphoid and bone marrow cells. Chem. Biol. Interact. 135-136 (2001) 615-625
48. Soloneski S., Gonzalez M., Piaggio E., Apezteguia M., Reigosa M.A., and Larramendy M.L. Effect of the dithiocarbamate pesticide zineb and its commercial formulation azzurro. I. Genotoxic evaluation on cultured human lymphocytes exposed in vitro. Mutagenesis 16 (2001) 487-493
49. Soloneski S., Reigosa M.A., and Larramendy M.L. Effect of dithiocarbamate pesticide zineb and its commercial formulation, azzurro. II. Micronucleus induction in immunophenotyped human lymphocytes. Environ. Mol. Mutagen. 40 (2002) 57-62
50. Schreck R., Meier B., Mannel D.N., Droge W., and Baeuerle P.A. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J. Exp. Med. 175 (1992) 1181-1194
51. Orrenius S., Nobel C.S.I., Van den Dobbelsteen D.J., Burkitt M.J., and Slater A.F.G. Dithiocarbamates and the redox regulation of cell death. Biochem. Soc. Trans. 24 (1996) 1032-1038
52. Naora H., Altin J.G., and Young I.G. Tcr-dependent and -independent signaling mechanisms differentially regulate lymphokine gene expression in the murine T helper clone D10.g4.1. J. Immunol. 152 (1994) 5691-5702
53. Jung C.K., Lee K.Y., Kim Y., Han K., Shim S.I., Kim B.K., and Kang C.S. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and Nk-cell lymphomas. Pathol. Int. 51 (2001) 355-363
54. Wu X., Bishopric N.H., Discher D.J., Murphy B.J., and Webster K.A. Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol. Cell. Biol. 16 (1996) 1035-1046
55. Powell M.J., Thompson S.A., Tone Y., Waldmann H., and Tone M. Posttranscriptional regulation of Il-10 gene expression through sequences in the 3′-untranslated region. J. Immunol. 165 (2000) 292-296
56. Pena M.M., Lee J., and Thiele D.J. A delicate balance: homeostatic control of copper uptake and distribution. J. Nutr. 129 (1999) 1251-1260
57. Varela-Nallar L., Toledo E.M., Larrondo L.F., Cabral A.L., Martins V.R., and Inestrosa N.C. Induction of cellular prion protein gene expression by copper in neurons. Am. J. Physiol. Cell Physiol. 290 (2006) C271-C281
58. Shiraishi N., Utsunomiya H., and Nishikimi M. Combination of Nadph and copper ions generates proteinase K-resistant aggregates from recombinant prion protein. J. Biol. Chem. 281 (2006) 34880-34887
59. Svane I.M., Boesen M., and Engel A.M. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors-lessons from normal and immunodeficient mice. Med. Oncol. 16 (1999) 223-238
60. Markiewicz M.A., and Gajewski T.F. The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit. Rev. Oncogen. 10 (1999) 247-260
61. Radoja S., and Frey A.B. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol. Med. 6 (2000) 465-479
62. Nast C.C., Moudgil A., Zuo X.J., Toyoda M., and Jordan S.C. Long-term allograft acceptance in a patient with posttransplant lymphoproliferative disorder: correlation with intragraft viral interleukin-10. Transplantation 64 (1997) 1578-1582
63. Birkeland S.A., Bendtzen K., Moller B., Hamilton-Dutoit S., and Andersen H.K. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 67 (1999) 876-881
64. Redpath S., Ghazal P., and Gascoigne N.R. Hijacking and exploitation of Il-10 by intracellular pathogens. Trends Microbiol. 9 (2001) 86-92
65. Garber K. Lymphoma rate rise continues to baffle researchers. J. Natl. Cancer Inst. 93 (2001) 494-496
66. Griffin B.E. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems. Mutat. Res. 462 (2000) 395-405
67. Kanno H., Naka N., Yasunaga Y., Iuchi K., Yamauchi S., Hashimoto M., and Aozasa K. Production of the immunosuppressive cytokine interleukin-10 by Epstein-Barr-virus-expressing pyothorax-associated lymphoma: possible role in the development of overt lymphoma in immunocompetent hosts. Am. J. Pathol. 150 (1997) 349-357
68. Flavell K.J., and Murray P.G. Hodgkin's disease and the Epstein-Barr virus. J. Clin. Pathol. Mol. Pathol. 53 (2000) 262-269